High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial-Reference-Cited by-同舟云学术

High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

Published:2022-05 Issue:5 Volume:23 Page:671-681
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zapatero Almudena,Guerrero Araceli,Maldonado Xavier,Álvarez Ana,San-Segundo Carmen González,Rodríguez María Ángeles Cabeza,Solé Josep María,Olivé Agustí Pedro,Casas Francesc,Boladeras Ana,de Vidales Carmen Martín,de la Torre María Luisa Vázquez,Vara Susana,Sanz Juan Luis,Calvo Felipe A

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610;Roach;J Clin Oncol,2008

2. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study;Bolla;Lancet Oncol,2010

3. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

4. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial;D'Amico;JAMA,2008

5. Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202;Lawton;Int J Radiat Oncol Biol Phys,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05);Practical Radiation Oncology;2024-09

2. Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China;BMC Urology;2024-08-29

3. Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer;Journal of Radiation Research;2024-08-17

4. Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer;Radiation Oncology Journal;2024-06-30

5. Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer;Japanese Journal of Radiology;2024-06-29